News Sentiment

RNA sentiment intelligence

Atrium Therapeutics, Inc. Common Stock news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 12.15 Week of 17 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 37

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-2.5% over one week, -4.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Atrium Therapeutics’ new hire receives options and 3,500 stock units

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction -2.5% Price reacting lower
Trend fit Trend inactive -4.0% over four weeks
Fair value -8.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 33
Negative 3

Relevance

Why the article matched

Direct first
Direct company coverage 37
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
Stock Titan 5
PR Newswire 5
TradingView 3
TradingKey 2
simplywall.st 2
Barron's 2
MT Newswires 1

Event Lens

What the news is about

Classified themes
Market update 21
Earnings 17
Deals and strategy 4
Regulatory and legal 1
Balance sheet 1
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-45 of 45
San Diego Business Journal Direct company coverage

Novartis, Avidity Deal Spins Out New RNA Co.

Atrium Therapeutics, a new RNA company, launched in February with $270 million in funding as a spinoff following Novartis' $12 billion acquisition of Avidity Biosciences. Atrium will focus on developing RNA therapeutics for rare muscle diseases, particularly in the precision card

Tone
Positive 71/100
Event
Deals and strategy
Published
09 Mar 2026 11:52
Source
San Diego Business Journal
Stock Titan Direct company coverage

RNAM SEC Filings - Avidity Biosciences, Inc. 10-K, 10-Q, 8-K Forms

This page provides access to Avidity Biosciences's (Ticker: RNAM) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It features AI-generated summaries, sentiment and impact scores from Rhea-AI, and end-of-day stock performance data to offer insights into market r

Tone
Neutral 50/100
Event
Market update
Published
09 Mar 2026 10:52
Source
Stock Titan
BioXconomy Direct company coverage

Atrium Therapeutics born from Novartis-Avidity deal to pioneer RNA therapies

Atrium Therapeutics has launched as an independent publicly traded company, spun off from Novartis' acquisition of Avidity Biosciences. The new company aims to develop RNA therapies for rare and life-threatening genetic cardiomyopathies, leveraging approximately $270 million in c

Tone
Neutral 50/100
Event
Deals and strategy
Published
04 Mar 2026 04:40
Source
BioXconomy
MarketBeat Direct company coverage

Avidity Biosciences, Inc. (NASDAQ:RNA) Receives Average Rating of "Hold" from Analysts

Avidity Biosciences, Inc. (NASDAQ:RNA) has received an average "Hold" rating from twenty-one analysts, with an average 12-month price target of $69.57. Recent insider selling of 58,407 shares worth $4.23 million was noted, alongside a Q3 earnings miss where EPS of ($1.59) and rev

Tone
Negative 33/100
Event
Earnings
Published
03 Mar 2026 09:52
Source
MarketBeat